Subsidy Information and Financing Scheme MSHLPemigatinib Tablet 4.5 mg, 9 mg, 13.5 mg Treatment of patients with locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or... See all × MSHLPemigatinib Tablet 4.5 mg, 9 mg, 13.5 mg Treatment of patients with locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement that has progressed after at least one prior line of systemic therapy.
ORAL Select a brand starting with the letter: P PEMAZYRE TABLETS 13.5 MG [SIN17044P] PEMAZYRE TABLETS 4.5 MG [SIN17042P] PEMAZYRE TABLETS 9 MG [SIN17043P]